US20060287285A1 - Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions - Google Patents
Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions Download PDFInfo
- Publication number
- US20060287285A1 US20060287285A1 US11/466,012 US46601206A US2006287285A1 US 20060287285 A1 US20060287285 A1 US 20060287285A1 US 46601206 A US46601206 A US 46601206A US 2006287285 A1 US2006287285 A1 US 2006287285A1
- Authority
- US
- United States
- Prior art keywords
- hormone
- symptom
- dilution
- progesterone
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Definitions
- One aspect of the present invention includes a previously unrecognized treatment for asthma, headache, sinus congestion, muscular pain, and bone and joint pain that involves desensitizing a body's response to its own innate hormones.
- the treatment may be applied to any mammal including humans.
- the mammal is female.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10−1 to 10−5. The hormone dilution may be administered sublingually, or, in the alternative, an intradermal route of administration may be chosen. Hormone dilutions may be administered at daily intervals or on any other treatment schedule as required to alleviate a patient's symptoms.
Description
- This application claims the benefit, under 35 U.S.C. § 119(e), of previously filed provisional application Methods And Compositions For The Treatment Of Allergy Using Dilute Hormone Solutions, Ser. No. 60/332,475, filed Nov. 16, 2001.
- The present invention relates in general to the treatment of pain and other hormone-allergy-related symptoms and in specific to the use of a dilute hormone solution for the treatment of pain and hormone-allergy symptoms.
- Hormone allergy has been previously described in the medical literature as premenstrual asthma. Skobeloff E. M., Spivey W. H., Silverman R. A., Ekin B. A., Harchelroad F. P., Alessi T. V.: The effect of the menstrual cycle on asthma presentations in the emergency department. Arch Intern Med 1996; 156: 1837-40. Claude F.: Asthma et menstruation. Presse Med 1938; 46: 755-759; Eliasson O., Scherzer H., DeGraff A. C.: Morbidity in asthma in relation to the menstrual cycle. J Allergy Clin Immunol 1986: 77: 87-94; Chandler M. H., Schuldheisz S., Phillips B., Muse K. N.: Pre-menstrual asthma: the effect of estrogen on symptoms, pulmonary function, and beta 2-receptors. Pharmacology 1997; 17(2): 224-234.
- Premenstrual asthma is a condition where premenstrual fluctuations in hormones such as estrogen and progesterone cause the exacerbation of clinical symptoms. Exacerbations of symptoms appear to occur during the premenstrual period when progesterone levels are high. Several references have been made to a possible reaction to hormones. The first report of hormonal influence on asthma symptoms appeared in a case report by Frank from 1931. Frank, R T: The hormonal causes of pre-menstrual tension. Arch Neurol Psychiatry 1931; 26: 1053-57. Severe aggravation of asthma symptoms in one patient were clearly linked to oral contraceptives. Derimov, G S, Oppenheimer J: Exacerbation of premenstrual asthma caused by an oral contraceptive. Ann Allergy Asthma Immunol 1998; 81: 243-46.
- Skobeloff et. al reported a four-fold increase in the presentation of asthmatic women to the emergency department during the perimenstrual interval (
days 26 to 04 of the menstrual cycle). When Skobeloff's data is superimposed over the hormone levels during the menstrual cycle, it shows that the peak emergency room visits occurred during the premenstrual period when the progesterone is highest relative to estrogen (FIG. 1 ). - There has been little investigation, however, into the systemic manifestations or treatment of hormone allergy, or the effect of hormones on organ systems other than the female reproductive tract. While there is documentation in the literature supporting the influence of hormones on premenstrual asthma, applicant knows of no established mode of action.
- In accordance with teachings of the present invention, a method and composition for treatment of hormone allergy using steroid hormone dilutions, specifically progesterone, estrogen and testosterone is provided.
- Observations that lead to and are a part of the present invention, suggest the possibility of an allergic reaction to the steroid hormone progesterone as a possible cause of clinical symptoms or premenstrual asthma and other disorders.
- One aspect of the present invention includes a previously unrecognized treatment for asthma, headache, sinus congestion, muscular pain, and bone and joint pain that involves desensitizing a body's response to its own innate hormones. The treatment may be applied to any mammal including humans. In an exemplary embodiment, the mammal is female.
- While hormones may fluctuate throughout the menstrual cycle, treatment is not limited to any specific point in the menstrual cycle. In an exemplary embodiment, however, dilute solutions of progesterone are administered sublingually, every day or every other day, as needed, until there is an alleviation of a patient's clinical symptoms. These dilute formulations are very similar to the type of dilutions that an allergist typically uses when treating allergic symptoms from external substances, or allergens, which are foreign to the body. However, in treating a patient with hormone allergy, instead of desensitizing the patient to a foreign substance, the patient is desensitized to his or her own innate hormone(s).
- Existing clinical treatments do not generally use sublingual administration of dilute hormone solutions to treat allergy symptoms. In addition, many of the symptoms that can be treated with hormone dilutions are not recognized as conventional allergy symptoms, such as bone and joint pain, muscular pain, and headache. Other symptoms which respond to treatment with hormone dilutions are recognized as classic allergy symptoms such as sinus congestion, ear and throat pain, eye and skin irritation.
- In accordance with another aspect of the present invention, dilutions of a hormone solution, such as progesterone are used to treat hormone allergy symptoms. A hormone dilution ranging in concentration from 5 mg/ml to 0.5 μg/ml is administered sublingually. The strength of the dilution selected for treatment may be based on the severity of the patient's symptoms and prior treatment history. The amount, frequency and strength of the hormone dilution may be varied depending on severity of symptoms and on response achieved.
- In an alternative embodiment of the invention, the route of administration may be intradermal.
- In accordance with a further aspect of this invention a dilute progesterone solution (
concentration 5 mg/ml to 0.5 μg/ml) or a dilute estrogen solution (concentration 5 mg/ml to 0.5 μg/ml) may be administered to treat hormone allergy symptoms in females. - In accordance with another aspect of this invention a dilute testosterone solution (
concentration 5 mg/ml to 0.5 μg/ml) may be used to treat allergy symptoms in males. Other steroid hormone solutions may also be used. All solutions of the present invention may be administered in a pharmaceutically-acceptable carrier. - A more complete and thorough understanding of the present invention and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, in which like reference numbers indicate like features, and wherein:
-
FIG. 1 illustrates the number of female asthmatic patient visits to an emergency department during the menstrual cycle; and -
FIG. 2 illustrates spirometry results of a patient before and after treatment with a dilute steroid hormone composition incorporating teachings of the present invention. - The present invention relates to a treatment of systemic allergic manifestations and pain caused at least in part by steroid hormones. Such manifestations have been observed and treated in female patients. For the condition of acute asthma alone, data on 83 patients treated with dilute progesterone has been collected. Measuring symptom response rate on a 10-point scale, a response rate of 93% overall was observed. The average reduction in symptom severity on the 10-point scale was 3.1 points. The present data show a 57% reduction in symptoms on average. These results are statistically significant at a level of p<0.0001.
- A composition of the present invention may include a standard solution of aqueous progesterone, or any other indicated steroid hormone, diluted with normal saline to achieve concentrations of 5 mg/ml to 0.5 μg/ml. The strength of a dilution selected for treatment may be based on a severity of the patient's symptoms and prior treatment history. This selection methodology may be similar to that used in treatments with foreign allergens and appropriate selections for an individual patient will be apparent to one skilled in the art.
- Typically, 0.1 cc of a hormone dilution (0.5 mg-0.05 μg per dose) is administered sublingually every other day. The frequency of administration may be increased to every day or more often, as required, to achieve a desired treatment response. The strength of the hormone dilution selected for treatment may also be varied depending on severity of symptoms and on response achieved. Response to therapy may be measured on a 10-point scale of symptom severity as reported by a patient to a clinical provider. Additional tests for abatement of symptoms may also be used. Treatment of hormone allergy symptoms may continue for months or years as indicated by each patient's clinical condition.
- In an alternative embodiment of this invention, the dilution may be administered intradermally for instance, in patients who may have no response to sublingual drops or are unable to use the sublingual delivery method.
- Progesterone USP 50 mg/ml (Schein Laboratories, Florham, N.J.) is diluted with physiologically-compatible (normal) saline to produce the progesterone dilutions used in treatments. The initial progesterone is suspended in sesame oil. Therefore, to achieve an even suspension, the vial must be vigorously shaken at each stage of the initial preparation and before use of each vial. The first dilution is made by adding 0.5 ml of progesterone to 4.5 ml normal saline. This results in a 1:10 dilution of progesterone (
progesterone 5 mg/ml) which is labeled “PROG 1.” After vigorously shaking thePROG 1 vial, 0.5 ml is withdrawn and injected into the next vial of 4.5 ml of normal saline. This results in a 1:100 dilution of Progesterone (0.5 mg/ml, “PROG 2”). To produce the next dilution, a vial ofPROG 2 is immediately withdraw 0.5 ml and injected into the next vial of 4.5 ml of normal saline. This results in a 1:1000 dilution of Progesterone (50 μg/ml “PROG 3”). These steps are repeated until there are five serial dilutions labeled “PROG 1” through “PROG 5.” (See Table 1). A milligram (mg) is defined as 1/1000 or 10−3 of a gram. A microgram (μg) is defined as 1/1,000,000 or 10−6 of a gram.TABLE 1 Progesterone Dilutions Dosage Progesterone Used Label Concentration Dilution (.1 ml) PROG 15 mg/ ml 10−1 .5 mg PROG 2 .5 mg/ ml 10−2 .05 mg PROG 3 50 μg/ ml 10−3 5 μg PROG 4 5 μg/ ml 10−4 .5 μg PROG 5 .5 μg/ ml 10−5 .05 μg - Before beginning treatment, all of a patient's symptoms are assessed and assigned a numerical value by the patient, based on a 10-point scale. Drops are administered to a patient in a standard sequence, starting with plain normal saline (NS) to assess the placebo effect. After plain normal saline,
PROG 5 is administered, followed byPROG 3, and then PROG 1. - After the drops are placed under a patient's tongue, the patient is instructed not to swallow for 5 seconds. Then the patient is asked to swallow the drops. After an additional 15 seconds, the patient is asked to note any change in any symptoms. The patient is questioned about each area of possible symptoms whether they are initially complained of or not. The question is always asked in the same manner, “Are your symptoms worse, unchanged, or better?” The question is asked in this way to always give the patient the option of selecting “worse” or “unchanged” before “better.” This is designed to minimize the power of suggestion or “placebo” effect.
- If all of the symptoms disappear completely after the placebo, the results are recorded and no further treatment is administered. If at any point, all the symptoms are relieved, the tests are concluded and the patient is provided with a vial with the same dilution of progesterone drops that relieved the symptoms. The patient is instructed to use the drops as often as needed. If symptom relief does not last 12-24 hours, this is an indication that the patient needs a vial one dilution stronger than what she is currently using.
- Patients are questioned about each of twelve standard categories of discomfort (see Table 2). If patients are only asked generally to describe their symptoms they will often omit symptoms that are not included in their chief complaint but that they are experiencing concomitantly with the chief complaint. The patient is asked to grade the symptoms on a scale of 1 to 10. “Zero” is no symptoms at all and “ten” is the most intense discomfort the patient has experienced with a symptom.
TABLE 2 Standard Template for Recording Response to Progesterone Dilutions Symptom Normal Location Saline PROG 5 PROG 3PROG 1Neck Nose Eyes Throat Shortness of Breath Headache Skin Ears Back Hips Lower Extremity Upper Extremity Other - The symptoms in Table 2 are defined as follows: “neck” refers to musculoskeletal pain in the neck, “nose” refers to blockage or stuffiness in the nose, “eyes” refers to irritation such as burning or itching, “shortness of breath” is defined as a patient's perception of the inability to take a deep breath, “headache” refers to pain in the head region, “skin” is defined as itching, burning or a rash on the skin, “ears” refers to pain or pressure in the ears, “back,” “hips,” “lower extremity” and “upper extremity” all refer to pain in those areas including arthritis-type pain or pain from chronic or acute injury.
- Data has been gathered on the clinical response to dilute progesterone therapy for over 300 patients. Patients presenting for treatment ranged in age from 30 to 70 years old and were predominantly female. See Table 3.
TABLE 3 Patient Demographics Age Range 30-70 years Male:Female 1:4 Progesterone Dosage 0.5 mg-.05 μg Length of Treatment 1-90 days - Patients generally responded favorably in the areas of both allergy and pain symptoms. In the area of allergy symptoms, 66-87% of patients responded depending on the site of allergy symptoms. See Table 4.
TABLE 4 Response to Treatment - Allergy Symptoms (N = 300) # of % Site Patients Responders Improvement % Responders Nose 109 89 63% 82% Eyes 90 73 57% 81% Throat 92 70 64% 76% Ear 35 23 52% 66% Skin 34 27 74% 79% Asthma/SOB 142 124 67% 87% - In the area of pain symptoms, 72-92% of patients responded depending on site of pain symptoms. See Table 5. Over half of the total patients in both groups responded with symptom relief in excess of 60%.
TABLE 5 Response to Treatment - Pain Symptoms (N = 300) No. of Percent Percent Site Patients Responders Improvement Responders Neck 144 104 62% 72% Headache 103 84 69% 82% Back 57 57 72% 82 % Hips 26 24 79% 92% Arm 61 48 76% 79% Leg 50 40 75% 80% - Progesterone antibody levels (immunoglobulins-IgG and IgM) have also been measured (Immunosciences Lab, Beverly Hills, Calif.) and are higher than normal range in approximately 70% of patients before treatment.
- Spirometry was performed on 22 patients with shortness of breath who were treated with dilute progesterone drops. All 22 had improvement in spirometry with hormonal allergy treatment. An example of the improvement is shown in
FIG. 2 which shows rate of air flow and lung volume in an individual patient pre- and post-treatment. Both the rate of air exchange (FIG. 2A , F(L/S)=air flow in liters per second) and the lung volume (FIG. 2B , V(L)=lung volume in liters, LLN=lower limits of normal for lung volume) of a female patient improved after dilute progesterone treatment in accordance with teachings of the present invention. - Although the present invention has been described with respect to specific preferred embodiments thereof, various changes and modifications may be suggested to one skilled in the art and it is intended that the present invention encompass such changes and modifications within the scope of the appended claims.
Claims (38)
1. A method for treating at least one symptom of a hormone allergy comprising administering sublingually to a patient in need an effective amount of a hormone dilution to treat the at least one symptom selected from the group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof.
2. The method of claim 1 wherein the hormone dilution comprises a steroid hormone solution with a concentration between approximately 5 mg/ml and 0.5 μg/ml.
3. The method of claim 2 further comprising the dilution of progesterone used to treat bone or joint pain.
4. The method of claim 2 further comprising the concentration of the hormone solution selected from the group consisting of 5 mg/ml, 0.5 mg/ml, 50 μg/ml, 5 μg/ml, and 0.5 μg/ml.
5. The method of claim 1 wherein the hormone dilution comprises an estrogen solution with a concentration between approximately 5 mg/ml and 0.5 μg/ml.
6. The method of claim 1 wherein the dilution comprises a progesterone solution with a concentration approximately between approximately 5 mg/ml and 0.5 μg/ml.
7. The method of claim 6 further comprising the amount of progesterone administered ranges from between approximately 0.5 mg to 0.05 μg per dose.
8. The method of claim 1 wherein the dilution comprises a testosterone solution with a concentration between approximately 5 mg/ml and 0.5 μg/ml.
9. The method of claim 1 wherein the at least one symptom comprises: headache, muscular pain in the head, neck, shoulders, back or legs, sinus symptoms, bone or joint pain, or any combination thereof.
10. The method of claim 1 further comprising administering the hormone dilution every day, every other day or as often as needed to alleviate symptoms.
11. A method for treating a hormone allergy comprising:
administering a dilution of progesterone with a concentration ranging between approximately 5 mg/ml to 0.5 μg/ml;
administering the dose sublingually to a patient; and
administering additional dilutions of progesterone as often as necessary to stimulate an effective response.
12. The method of claim 11 further comprising treating a symptom selected from the group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof.
13. A method of blocking pain perception in a patient's brain comprising administering sublingually a dilute hormone solution with a concentration between approximately 5 mg/ml and 0.5 μg/ml of the hormone.
14. The method of claim 13 wherein the hormone solution comprises dilute progesterone.
15. The method of claim 13 wherein the hormone solution comprises dilute estrogen.
16. The method of claim 13 wherein in the hormone solution comprises dilute testosterone.
17. A method of determining an appropriate sublingual steroid hormone dilution for treatment of a hormone allergy comprising:
ranking the severity of at least one symptom;
administering sublingually increasing concentrations of a dilute hormone solution to a patient;
ranking the severity of the at least one symptom again after sublingual administration of each concentration of the steroid hormone dilution;
each concentration of the steroid hormone dilution between approximately 5 mg/ml and 0.5 μg/ml; and
the concentration at which symptoms improve or are alleviated corresponding with an appropriate dose for a respective patient.
18. The method of claim 17 wherein the steroid hormone comprises progesterone.
19. The method of claim 17 further comprising ranking the symptom using a numeric scale.
20. The method of claim 17 further comprising the increasing concentrations of hormone dilution from approximately between 0.5 μg/ml, 5 μg/ml, 50 μg/ml, 0.5 mg/ml, and 5 mg/ml.
21. A composition for the treatment of hormone allergy comprising:
a hormone solution having a concentration between approximately 0.5 μg/ml and 5 mg/ml;
the hormone solution including at least normal saline; and
the hormone solution operable to treat a symptom from a group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof.
22. The composition of claim 21 wherein the hormone comprises progesterone.
23. The composition of claim 21 wherein the hormone comprises testosterone.
24. A composition for the treatment of hormone allergy comprising:
a hormone solution with a concentration between approximately 0.5 μg/ml and 5 mg/ml;
the hormone solution operable to be administered sublingually;
the hormone solution operable to treat at least one symptom from a group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof; and
severity of the symptom ranked before treatment by a patient.
25. The composition of claim 24 wherein the hormone comprises progesterone.
26. The composition of claim 24 wherein the hormone comprises testosterone.
27. The composition of claim 24 comprising the at least one symptom ranked with a numeric scale.
28. A method for treating pain comprising:
administering a dilution of progesterone with a concentration ranging from between approximately 5 mg/ml to 0.5 μg/ml;
administering the dose sublingually to a patient; and
administering additional dilutions of progesterone as often as necessary to stimulate an effective response.
29. The method of claim 28 further comprising treating a symptom selected from the group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof.
30. A method of determining an appropriate sublingual steroid hormone dilution for treatment of pain comprising:
ranking the severity of at least one symptom;
administering sublingually increasing concentrations of a dilute hormone solution to a patient;
ranking the severity of the at least one symptom again after sublingual administration of each concentration of the steroid hormone dilution;
each concentration of the steroid hormone dilution between approximately 5 mg/ml and 0.5 μg/ml; and
the concentration at which symptoms improve or are alleviated corresponding with an appropriate dose for a respective patient.
31. The method of claim 30 wherein the steroid hormone comprises progesterone.
32. The method of claim 30 further comprising ranking the symptom using a numeric scale.
33. The method of claim 30 further comprising the increasing concentrations of hormone dilution from approximately between 0.5 μg/ml, 5 μg/ml, 50 μg/ml, 0.5 mg/ml, and 5 mg/ml.
34. The method of claim 30 further comprising the amount of progesterone administered ranges from between approximately 0.5 mg to 0.05 μg.
35. A method for treating at least one symptom of a hormone allergy comprising administering sublingually to a patient in need an effective amount of a hormone dilution, wherein the at least one symptom is selected from the group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof and wherein relief of the at least one symptom occurs in about 20 seconds after administration.
36. A method for treating at least one symptom of a hormone allergy comprising administering sublingually to a subject about 0.1 milliliter of a 0.05 milligram per milliliter dilution of a hormone selected from the group consisting of estrogen and progesterone, wherein the at least one symptom is selected from the group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof, wherein relief of the at least one symptom occurs in about 20 seconds after administration, and wherein the subject experiences at least about a 57% reduction in the at least one symptom on average.
37. A method for treating at least one symptom of a hormone allergy comprising administering sublingually to a subject about 0.1 milliliter of a 0.05 milligram per milliliter dilution of a hormone selected from the group consisting of estrogen and progesterone, wherein the at least one symptom is selected from the group consisting of shortness of breath, nasal congestion, eye irritation, headache, pain in the head, neck, shoulders, back, arms, legs and joints and any combination thereof, wherein relief of the at least one symptom occurs in about 20 seconds after administration and lasts for at least about twelve to about twenty-four hours.
38. A method for treating at least one symptom of a hormone allergy comprising administering sublingually to a patient in need an effective amount of a hormone dilution, wherein the at least one symptom comprises shortness of breath, wherein relief of the at least one symptom occurs in about 20 seconds after administration, and wherein the subject's air flow, lung volume, or both air flow and lung volume are higher after treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/466,012 US20060287285A1 (en) | 2001-11-16 | 2006-08-21 | Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33247501P | 2001-11-16 | 2001-11-16 | |
US10/294,512 US7179798B2 (en) | 2001-11-16 | 2002-11-14 | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
US11/466,012 US20060287285A1 (en) | 2001-11-16 | 2006-08-21 | Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/294,512 Division US7179798B2 (en) | 2001-11-16 | 2002-11-14 | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060287285A1 true US20060287285A1 (en) | 2006-12-21 |
Family
ID=26968578
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/294,512 Expired - Fee Related US7179798B2 (en) | 2001-11-16 | 2002-11-14 | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
US11/466,012 Abandoned US20060287285A1 (en) | 2001-11-16 | 2006-08-21 | Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/294,512 Expired - Fee Related US7179798B2 (en) | 2001-11-16 | 2002-11-14 | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
Country Status (5)
Country | Link |
---|---|
US (2) | US7179798B2 (en) |
EP (1) | EP1450815A4 (en) |
AU (1) | AU2002348299A1 (en) |
CA (1) | CA2466927A1 (en) |
WO (1) | WO2003043579A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
WO2005105107A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of multiple sclerosis |
WO2005105106A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of macular degeneration |
US20060025390A1 (en) * | 2004-07-28 | 2006-02-02 | Roby Russell R | Treatment of hormone allergy and related symptoms and disorders |
KR20080014056A (en) | 2005-05-20 | 2008-02-13 | 오메로스 코포레이션 | Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures |
US20110262365A1 (en) * | 2008-11-13 | 2011-10-27 | Alek Itsekson | Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US550174A (en) * | 1895-11-19 | hodder | ||
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US5084277A (en) * | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5744463A (en) * | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
US5834521A (en) * | 1995-03-09 | 1998-11-10 | Ortho Pharmaceutical Corporation | Substituted dibenz (A F)azulenes and methods of preparation |
US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
US5869081A (en) * | 1996-06-28 | 1999-02-09 | The Population Council | Progesterone vaginal ring for treatment of infertility |
US6040340A (en) * | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
US6043236A (en) * | 1995-08-23 | 2000-03-28 | Astra Aktiebolag | Estrogens |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6290957B1 (en) * | 1997-07-02 | 2001-09-18 | Genentech Inc | Anti-IgE antibodies and method of improving polypeptides |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US20020164314A1 (en) * | 2001-03-02 | 2002-11-07 | Neurostasis, Inc. | Ovarian hormone induced neural stem cell increase |
US20030148987A1 (en) * | 2001-12-21 | 2003-08-07 | Morris David J. | Selective 11beta-HSD inhibitors and methods of use thereof |
US20040105858A1 (en) * | 2002-08-29 | 2004-06-03 | Kim Joanne Young Hee Kwak | Diagnosis and treatment of infertility |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
US20070037782A1 (en) * | 2003-09-29 | 2007-02-15 | Meiji Dairies Corporation | Therapeutic agent for ageing macular degeneration |
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
GB9611192D0 (en) | 1996-05-29 | 1996-07-31 | Medical Res Council | Use |
DE19654750A1 (en) | 1996-12-30 | 1998-07-02 | Helmut Dr Med Zander | Use of active ingredients with an estrogenic effect for the prevention and treatment of macular degeneration |
-
2002
- 2002-11-14 US US10/294,512 patent/US7179798B2/en not_active Expired - Fee Related
- 2002-11-18 AU AU2002348299A patent/AU2002348299A1/en not_active Abandoned
- 2002-11-18 CA CA002466927A patent/CA2466927A1/en not_active Abandoned
- 2002-11-18 EP EP02782324A patent/EP1450815A4/en not_active Withdrawn
- 2002-11-18 WO PCT/US2002/037105 patent/WO2003043579A2/en not_active Application Discontinuation
-
2006
- 2006-08-21 US US11/466,012 patent/US20060287285A1/en not_active Abandoned
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US550174A (en) * | 1895-11-19 | hodder | ||
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5084277A (en) * | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5834521A (en) * | 1995-03-09 | 1998-11-10 | Ortho Pharmaceutical Corporation | Substituted dibenz (A F)azulenes and methods of preparation |
US6043236A (en) * | 1995-08-23 | 2000-03-28 | Astra Aktiebolag | Estrogens |
US6040340A (en) * | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
US5744463A (en) * | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
US5869081A (en) * | 1996-06-28 | 1999-02-09 | The Population Council | Progesterone vaginal ring for treatment of infertility |
US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
US6290957B1 (en) * | 1997-07-02 | 2001-09-18 | Genentech Inc | Anti-IgE antibodies and method of improving polypeptides |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US20020164314A1 (en) * | 2001-03-02 | 2002-11-07 | Neurostasis, Inc. | Ovarian hormone induced neural stem cell increase |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
US20030148987A1 (en) * | 2001-12-21 | 2003-08-07 | Morris David J. | Selective 11beta-HSD inhibitors and methods of use thereof |
US20040105858A1 (en) * | 2002-08-29 | 2004-06-03 | Kim Joanne Young Hee Kwak | Diagnosis and treatment of infertility |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
US20070037782A1 (en) * | 2003-09-29 | 2007-02-15 | Meiji Dairies Corporation | Therapeutic agent for ageing macular degeneration |
Also Published As
Publication number | Publication date |
---|---|
WO2003043579A2 (en) | 2003-05-30 |
EP1450815A4 (en) | 2005-04-13 |
US7179798B2 (en) | 2007-02-20 |
US20030096801A1 (en) | 2003-05-22 |
AU2002348299A1 (en) | 2003-06-10 |
EP1450815A2 (en) | 2004-09-01 |
WO2003043579A3 (en) | 2003-12-24 |
CA2466927A1 (en) | 2003-05-30 |
AU2002348299A8 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060287285A1 (en) | Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions | |
Hebert et al. | Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐and placebo‐controlled study | |
Meltzer et al. | A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis | |
WO2000045801A2 (en) | Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain | |
Aaronson | Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma | |
Pulec et al. | Progressive sensorineural hearing loss, subjective tinnitus and vertigo caused by elevated blood lipids | |
Cundill | Hormone therapy for trans and gender diverse patients in the general practice setting | |
Nathan et al. | Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis | |
Lim et al. | Allergic rhinitis: evidence-based practice | |
Laforce et al. | Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents | |
Raphael et al. | A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma | |
US6495529B1 (en) | (−)-Pseudoephedrine as a sympathomimetic drug | |
Rasor et al. | Addiction to meperidine (Demerol) hydrochloride | |
Willsie | Improved strategies and new treatment options for allergic rhinitis | |
Schaaf et al. | Suppression of seasonal allergic rhinitis symptoms with daily hydroxyzine | |
Sabbah et al. | Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children | |
US6762193B1 (en) | Method of treating hair loss | |
Cingi et al. | Update on the medical treatment of allergic rhinitis | |
McAllen et al. | Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis | |
Dirks et al. | Death in asthma: A psychosomatic autopsy | |
Pulec | Meniere's disease of syphilitic etiology | |
Kaiser et al. | Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis | |
US20080242733A1 (en) | (-)-Pseudoephedrine as a sympathomimetic drug | |
US20050065136A1 (en) | Methods and compositions for the treatment of infertility using dilute hormone solutions | |
CA2133563C (en) | Use of hydriodic acid as an aphrodisiac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |